For help on how to get the results you want, see our search tips.
280 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Orphan designations Remove Orphan designations filter
Summaries of opinion Remove Summaries of opinion filter
Withdrawn applications Remove Withdrawn applications filter
Categories
Human Remove Human filter
Medicine type
Conditional approval Remove Conditional approval filter
Generic Remove Generic filter
Exceptional circumstances Remove Exceptional circumstances filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Apotex)
clopidogrel (as besilate), Peripheral Vascular Diseases, Stroke, Myocardial Infarction
Date of authorisation: 16/10/2009,
, Revision: 20, Authorised, Last updated: 17/02/2021
-
List item
Human medicine European public assessment report (EPAR): Lenalidomide Accord
lenalidomide, Multiple Myeloma
Date of authorisation: 20/09/2018,, Revision: 5, Authorised, Last updated: 17/02/2021
-
List item
Human medicine European public assessment report (EPAR): Darunavir Mylan
darunavir, HIV Infections
Date of authorisation: 03/01/2017,, Revision: 8, Authorised, Last updated: 16/02/2021
-
List item
Human medicine European public assessment report (EPAR): Mysildecard
sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 15/09/2016,, Revision: 3, Authorised, Last updated: 15/02/2021
-
List item
Human medicine European public assessment report (EPAR): Lamivudine/Zidovudine Teva
lamivudine, zidovudine, HIV Infections
Date of authorisation: 28/02/2011,, Revision: 12, Authorised, Last updated: 11/02/2021
-
List item
Human medicine European public assessment report (EPAR): Tenofovir disoproxil Mylan
tenofovir disoproxil, HIV Infections
Date of authorisation: 08/12/2016,, Revision: 12, Authorised, Last updated: 11/02/2021
-
List item
Human medicine European public assessment report (EPAR): Levetiracetam Actavis Group
levetiracetam, Epilepsy
Date of authorisation: 04/12/2011,, Revision: 14, Authorised, Last updated: 10/02/2021
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz GmbH
pregabalin, Anxiety Disorders, Epilepsy
Date of authorisation: 19/06/2015,, Revision: 7, Authorised, Last updated: 10/02/2021
-
List item
Human medicine European public assessment report (EPAR): Duloxetine Zentiva
duloxetine, Anxiety Disorders, Depressive Disorder, Major, Neuralgia, Diabetes Mellitus
Date of authorisation: 20/08/2015,, Revision: 8, Authorised, Last updated: 10/02/2021
-
List item
Human medicine European public assessment report (EPAR): Levetiracetam Accord
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,, Revision: 12, Authorised, Last updated: 10/02/2021
-
List item
Human medicine European public assessment report (EPAR): Pemetrexed Fresenius Kabi
pemetrexed, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Date of authorisation: 22/07/2016,, Revision: 10, Authorised, Last updated: 10/02/2021
-
List item
Human medicine European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 26/11/2009,, Revision: 18, Authorised, Last updated: 05/02/2021
-
List item
Human medicine European public assessment report (EPAR): Desloratadine ratiopharm
desloratadine, Rhinitis, Allergic, Perennial, Urticaria, Rhinitis, Allergic, Seasonal
Date of authorisation: 13/01/2012,, Revision: 9, Authorised, Last updated: 03/02/2021
-
List item
Human medicine European public assessment report (EPAR): Mycophenolate mofetil Teva
mycophenolate mofetil, Graft Rejection
Date of authorisation: 21/02/2008,, Revision: 22, Authorised, Last updated: 03/02/2021
-
List item
Human medicine European public assessment report (EPAR): Raloxifene Teva
raloxifene hydrochloride, Osteoporosis, Postmenopausal
Date of authorisation: 29/04/2010,, Revision: 9, Authorised, Last updated: 03/02/2021
-
List item
Human medicine European public assessment report (EPAR): Pregabalin Mylan Pharma
pregabalin, Anxiety Disorders, Neuralgia, Epilepsy
Date of authorisation: 25/06/2015,, Revision: 7, Authorised, Last updated: 02/02/2021
-
List item
Human medicine European public assessment report (EPAR): Amlodipine / Valsartan Mylan
Amlodipine besilate, valsartan, Hypertension
Date of authorisation: 22/03/2016,, Revision: 6, Authorised, Last updated: 02/02/2021
-
List item
Human medicine European public assessment report (EPAR): Bosulif
bosutinib (as monohydrate), Leukemia, Myeloid
Date of authorisation: 27/03/2013,
, 
, Revision: 20, Authorised, Last updated: 29/01/2021
-
List item
Human medicine European public assessment report (EPAR): Imatinib Teva
imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Hypereosinophilic Syndrome, Dermatofibrosarcoma
Date of authorisation: 07/01/2013,, Revision: 15, Authorised, Last updated: 29/01/2021
-
List item
Human medicine European public assessment report (EPAR): Entecavir Accord
Entecavir, Hepatitis B, Chronic
Date of authorisation: 25/09/2017,, Revision: 3, Authorised, Last updated: 29/01/2021
-
List item
Human medicine European public assessment report (EPAR): Potactasol
topotecan, Uterine Cervical Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 06/01/2011,, Revision: 8, Authorised, Last updated: 29/01/2021
-
List item
Human medicine European public assessment report (EPAR): Defitelio
defibrotide, Hepatic Veno-Occlusive Disease
Date of authorisation: 18/10/2013,, 
, 
, Revision: 13, Authorised, Last updated: 28/01/2021
-
List item
Human medicine European public assessment report (EPAR): Zynteglo
Autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene, beta-Thalassemia
Date of authorisation: 29/05/2019,, 
, , , Revision: 3, Authorised, Last updated: 28/01/2021
-
List item
Human medicine European public assessment report (EPAR): Lorviqua
Lorlatinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/05/2019,, , Revision: 5, Authorised, Last updated: 28/01/2021
-
List item
Human medicine European public assessment report (EPAR): Telmisartan Teva Pharma
telmisartan, Hypertension
Date of authorisation: 03/10/2011,, Revision: 9, Authorised, Last updated: 28/01/2021